Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 79 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vitiligo Clear all
Completed Phase 3 Interventional

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526
View directory record Official record
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

NCT05298033
View directory record Official record
Conditions
Vitiligo
Interventions
Crisaborole 2 % Topical Ointment, PF-07038124 0.01% topical ointment, NBUVB phototherapy, Sham phototherapy, Vehicle
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 3 Interventional Results available

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

NCT04530344
View directory record Official record
Conditions
Vitiligo
Interventions
ruxolitinib, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
44
States / cities
Hoover, Alabama • Gilbert, Arizona • Fountain Valley, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Not applicable Interventional Results available

Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions

NCT04547998
View directory record Official record
Conditions
Vitiligo
Interventions
Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
Device
Lead sponsor
Avita Medical
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Irvine, California • Sacramento, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 21, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

An Open-label Single Center, Proof of Concept Study Evaluating the Efficacy of Roflumilast Foam 0.3% in Pediatric Patients With Non-Segmental Vitiligo (NSV)

NCT07105254
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
Roflumilast topical 0.3% foam
Drug
Lead sponsor
Derm Texas, PLLC
Network
Eligibility
2 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 1 Interventional

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

NCT01430195
View directory record Official record
Conditions
Vitiligo
Interventions
Afamelanotide, Narrow-Band UVB Light Treatment
Drug · Procedure
Lead sponsor
Clinuvel Pharmaceuticals Limited
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Oct 21, 2026, 2:46 PM EDT
Not listed No phase listed Observational

A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions

NCT05084417
View directory record Official record
Conditions
Atopic Dermatitis, Dermatology, Vitiligo, Alopecia Areata, Hidradenitis Suppurativa, Psoriasis
Interventions
N/A This is an observational study
Other
Lead sponsor
OM1, Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 21, 2026, 2:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo

NCT01401374
View directory record Official record
Conditions
Vitiligo Vulgaris
Interventions
Not listed
Lead sponsor
St. Luke's-Roosevelt Hospital Center
Other
Eligibility
Not listed
Enrollment
3,258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 21, 2026, 2:46 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study of Patients With Dermatologic Disease

NCT07748169
View directory record Official record
Conditions
Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
Interventions
Not listed
Lead sponsor
Target PharmaSolutions, Inc.
Industry
Eligibility
Not listed
Enrollment
2,000,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo

NCT03123016
View directory record Official record
Conditions
Vitiligo
Interventions
Apremilast, NB-UVB phototherapy
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

Topical Ruxolitinib for the Treatment of Vitiligo

NCT02809976
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib 1.5% Phosphate Cream
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 21, 2026, 2:46 PM EDT
Recruiting Phase 2 Interventional

Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients

NCT07223229
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
EI-001, Placebo
Biological · Other
Lead sponsor
Elixiron Immunotherapeutics (Hong Kong) Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Huntington Beach, California • Hollywood, Florida • Worcester, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Stress Response Pathways in Vitiligo

NCT02797574
View directory record Official record
Conditions
Vitiligo
Interventions
Punch Biopsy at a Lesional Site, Punch Biopsy at a Non- Lesional site
Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 4 Interventional

NB-UVB and PUVA Vitiligo Study

NCT01732965
View directory record Official record
Conditions
Vitiligo
Interventions
Phototherapy, Phototherapy and Photochemotherapy
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 21, 2026, 2:46 PM EDT
Active, not recruiting Phase 3 Interventional

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411
View directory record Official record
Conditions
Vitiligo
Interventions
Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

NCT04103060
View directory record Official record
Conditions
Vitiligo
Interventions
Cerdulatinib 0.37% gel, Vehicle gel
Drug
Lead sponsor
Dermavant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Irvine, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

NCT04818346
View directory record Official record
Conditions
NonSegmental Vitiligo
Interventions
INCB054707, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
23
States / cities
Hoover, Alabama • Gilbert, Arizona • Scottsdale, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)

NCT04896385
View directory record Official record
Conditions
Vitiligo
Interventions
Ruxolitinib cream, Vehicle Cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Fountain Valley, California • Irvine, California • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2025 · Synced Oct 21, 2026, 2:46 PM EDT
Active, not recruiting Phase 3 Interventional

A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo

NCT06163326
View directory record Official record
Conditions
Vitiligo
Interventions
Ritlecitinib, Ritlecitinib 100 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 2:46 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy

NCT00771355
View directory record Official record
Conditions
Vitiligo, Melasma, Hyperpigmentation, Hypopigmentation
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 30, 2011 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effect of Microneedling, Bimatoprost and Excimer in Vitiligo Treatment

NCT04738149
View directory record Official record
Conditions
Vitiligo
Interventions
Bimatoprost, Excimer laser, Microneedling with a dermaroller
Drug · Device
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2022 · Synced Oct 21, 2026, 2:46 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

NCT03715829
View directory record Official record
Conditions
Active Non-segmental Vitiligo
Interventions
PF-06651600, placebo, PF06700841, narrow-band UVB phototherapy
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
40
States / cities
Huntington Beach, California • Irvine, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2022 · Synced Oct 21, 2026, 2:46 PM EDT
Not listed Phase 2 Interventional

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

NCT05210582
View directory record Official record
Conditions
Vitiligo
Interventions
Afamelanotide
Drug
Lead sponsor
Clinuvel, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 21, 2026, 2:46 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

NCT05635266
View directory record Official record
Conditions
Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Interventions
Specimen sample
Diagnostic Test
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 21, 2026, 2:46 PM EDT